NEW YORK (GenomeWeb) – New results from an ongoing trial support expanded utility of Agendia's breast cancer tests for stratifying patients and personalizing their treatment.
The data, from the I-SPY 2 trial, were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland on Wednesday by Laura van 't Veer, chief research officer of Agendia and a professor at the University of California, San Francisco.